NexGel $2 Target Means 284.69% Upside Over Bluejay

For biotech investors screening small-cap medtech, this head-to-head is less about a single catalyst and more about which balance sheet can fund the next regulatory milestone. NexGel appears to have that edge: higher revenue, higher earnings, a lower P/E, and a consensus target implying 284.69% upside. Bluejay's diagnostic story may have institutional backing, but its weaker profitability and valuation make it the riskier clinical-stage bet.

A comparative review published June 28, 2026 using MarketBeat data concludes that NexGel (NASDAQ:NXGL) is the superior small-cap medical company relative to Bluejay Diagnostics (NASDAQ:BJDX), winning 9 of 13 factors. The most striking figure is NexGel's consensus target price of $2.00, which at the time of publication implied 284.69% upside. That translates to a then-current share price near $0.52. Bluejay's price target is not disclosed in the source text, but its weaker consensus rating and profitability suggest a less attractive setup.

“

Ownership composition reveals a notable split: Bluejay has 18.5% institutional ownership and only 6.1% insider ownership, whereas NexGel has just 2.2% institutional ownership but 23.4% insider ownership.

Both stocks carry low beta—Bluejay 0.82 and NexGel 0.74—meaning they are 18% and 26% less volatile than the S&P 500, respectively. That is atypical for micro-cap medical companies and may reflect thin trading and limited investor attention rather than genuine defensiveness. Ownership composition reveals a notable split: Bluejay has 18.5% institutional ownership and only 6.1% insider ownership, whereas NexGel has just 2.2% institutional ownership but 23.4% insider ownership. The conventional MarketBeat narrative frames institutional ownership as a bullish long-term signal, which favors Bluejay. But the insider concentration at NexGel is a double-edged sword—it aligns management with shareholders but can also signal illiquidity or a lack of external validation. For small-cap medical companies, high insider ownership often appears in pre-commercial or turnaround stories, while institutional presence indicates an investable float.

Profitability and valuation tell a clearer story. NexGel reports higher revenue and earnings than Bluejay and trades at a lower price-to-earnings ratio. The sources do not provide absolute figures, but the directional superiority across net margins, return on equity, and return on assets supports the 9-of-13 factor win. This suggests NexGel has a more mature or better-capitalized operation, while Bluejay may still be burning cash on diagnostic development.

For context, Bluejay Diagnostics is described as a medical diagnostic company; NexGel's name and classification point to hydrogel-based medical products, though the source text truncates before detailing the pipeline. That limits clinical inference. Still, the market-trends framing is useful: 2025–2026 has been difficult for small-cap healthcare, with capital moving toward larger, later-stage assets and away from speculative diagnostics. In that environment, a company with positive earnings and a lower P/E—NexGel—offers relative safety, while a diagnostics pure-play like Bluejay faces a higher bar for financing and commercialization.